Phase 3 results highlight metabolic benefits alongside weight loss

Late‑breaking EULAR results highlight sustained responses through week 52

Commission authorisation expands access to passive measles prophylaxis for vulnerable patients

Early clinical activity supports expansion into broader IgA‑mediated conditions

Adding durvalumab to chemoradiation helps people avoid having their bladder removed

New collaboration aims to break barriers in brain‑targeted drug discovery

Aragen scales Daretabart to commercial-ready production following rapid 9‑month tech transfer

Data shows survival benefit in BRAFV600E‑mutant metastatic colorectal cancer

Findings strengthen rationale for EMERALD trial of engineered macrophage therapy RTX001

Phase 1 study to assess safety and early efficacy of KMA‑targeting car‑t in multiple myeloma